Q-omics provides the consensus-scored SINHCAF profile across patient tissues and cancer cell-line models. SINHCAF expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SINHCAF is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, SINHCAF RNA expression shows 20,006 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight CESC, BLCA, and KIRP as cancer lineages where SINHCAF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SINHCAF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SINHCAF survival associations across molecular data types. SINHCAF RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SINHCAF RNA expression–survival associations across cancer types. High SINHCAF expression shows unfavorable associations in CESC, PAAD, ACC and LIHC, but favorable associations in GBM and LGG. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify CESC as the clearest survival context for SINHCAF RNA expression.
This table summarizes SINHCAF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SINHCAF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SINHCAF shows lower tumor expression in KIRC and higher tumor expression in BLCA, COAD, LUAD, HNSC and STAD. The BLCA box plot shows higher SINHCAF RNA expression in tumor versus normal tissue (log2 FC = +1.784, t-test p < 0.001).
This table shows molecular features associated with SINHCAF in patient tissues and cancer cell lines. In patient samples, SINHCAF shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SINHCAF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
